At Eisai Europe, human health care is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides. We have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs.
To learn more, visit www.eisai.eu.
Join our Eisai-sponsored symposium and workshop
As part of the ILCA 2021 virtual programme, Eisai will be sponsoring a symposium and case studies workshop with leading experts to discuss the role of first-line monotherapy in unresectable hepatocellular carcinoma (uHCC). These sessions are aimed at healthcare professionals.
Session 1: Symposium – Saturday 4th September 13:00 – 14:00 CET (and on demand)
The role of first-line monotherapy in a uHCC combination market
Join us for Eisai’s sponsored symposium where a panel of leading experts will discuss the role of first-line monotherapy in a rapidly evolving treatment landscape, followed by a live Q&A. With combination therapies expected to become the standard of care in first-line uHCC, our panel will cover a variety of topics including patient selection, clinical considerations, and the future treatment landscape.
Session 2: Case studies workshop – Available on demand from Monday 6th September
A case studies approach: The role of first-line monotherapy in a uHCC combination market
Our panel of experts will present cases depicting their clinical experiences of treating HCC patients with first-line monotherapy. This workshop-style session includes discussion around treatment selection, response to treatment and the place for monotherapy in the future treatment landscape.
uHCC: unresectable hepatocellular carcinoma.
GL-LENA-21-00023 July 2021